Market research
6160.HK BeiGene, Ltd
Current ticker: 6160.HK
HK HKD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 338B
- P/E ratio
- 67.98
- Analyst target
- 265.4535
- Dividend yield
- Not available
- Beta
- 0.61
Profile
Instrument facts
- Exchange
- HK
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- KYG1146Y1017
- Market cap
- 338B
- P/E ratio
- 67.98
- Analyst target
- 265.4535
- Dividend yield
- Not available
- Beta
- 0.61
About
About BeiGene, Ltd
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
Research context
BeiGene, Ltd appears in PyInvesting’s Hong Kong Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 6160.HK discussion.
5 years, 6 months ago
BeiGene, Ltd is currently in a long term uptrend where the price is trading 0.1% above its 200 day moving average.
From a valuation standpoint, the stock is 21.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 88.5.
BeiGene, Ltd's total revenue rose by 75.9% to $100M since the same quarter in the previous year.
Its net income has dropped by 21.8% to $-473M since the same quarter in the previous year.
Finally, its free cash flow fell by 28.5% to $-389M since the same quarter in the previous year.
Based on the above factors, BeiGene, Ltd gets an overall score of 3/5.